Runcaciguat

A pharmaceutical drug used in the treatment of chronic kidney disease

Runcaciguat
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Runcaciguat is a pharmaceutical compound that acts as a soluble guanylate cyclase (sGC) activator. It is primarily under investigation for its potential therapeutic effects in treating chronic kidney disease (CKD) and other related conditions.

Mechanism of Action

Runcaciguat functions by directly stimulating the enzyme soluble guanylate cyclase, which is a key component in the nitric oxide (NO) signaling pathway. This pathway is crucial for various physiological processes, including vasodilation and regulation of blood pressure. By activating sGC, runcaciguat increases the levels of cyclic guanosine monophosphate (cGMP), leading to vasodilation and improved blood flow, which can be beneficial in conditions like CKD where blood flow to the kidneys is compromised.

Clinical Development

Runcaciguat is currently undergoing clinical trials to evaluate its efficacy and safety in patients with chronic kidney disease. The drug is being studied for its potential to slow the progression of CKD and improve renal function by enhancing blood flow and reducing oxidative stress in the kidneys.

Potential Benefits

The activation of sGC by runcaciguat may offer several benefits in the management of CKD:

• Improved Renal Blood Flow: By promoting vasodilation, runcaciguat can enhance blood flow to the kidneys, potentially improving kidney function.
• Reduction of Oxidative Stress: Increased cGMP levels can help reduce oxidative stress, which is a contributing factor in the progression of CKD.
• Blood Pressure Regulation: As a vasodilator, runcaciguat may aid in the management of hypertension, a common comorbidity in CKD patients.

Side Effects and Safety

As with any pharmaceutical agent, runcaciguat may have side effects. Commonly reported side effects in clinical trials include headache, dizziness, and hypotension. The safety profile of runcaciguat is still being evaluated in ongoing studies.

Related Pages

• Chronic kidney disease
• Guanylate cyclase
• Vasodilation
• Nitric oxide